Phesi

This is inspiring writing for a Friday read. We used to spend $2.7 billion to sequence a person’s DNA. That price has now dropped to $200! That potential is absolutely real for clinical development. Riding on big data and artificial intelligence, we can now be guided by what we have learned from contextualized data from 130 million patients worldwide, to avoid clinical trial design and investigator site selection mistakes and minimize patient exposure to placebo or potentially inferior comparator through a digital twin/external control arm. Join us to go DIGITAL! Congratulations to Colin Hill of Aitia for this nice piece. Phesi #clinicaldevelopment #clinicaltrials #bigdata #artificialintelligence

?? Our Founder and President, Gen Li, PhD, MBA, sat down with Pharmaceutical Executive to discuss the growing issue of non-active and non-enrolling investigator sites in #ClinicalDevelopment. Selecting the best investigator sites has always been challenging, but the clinical development industry is approaching a crisis point.??? In the Q&A, Gen emphasizes that sponsors must adopt a data-driven approach to #ClinicalTrial design to identify the most experienced investigators, select investigator sites with precision, and ultimately increase the success rate of trials. ?? Read the full piece here: https://lnkd.in/eyNMAXyd

We're proud to see our team member supporting this worthwhile cause. Well done Nate Collins

Our new global analysis found that Phase III clinical trials are over-collecting data due to overcomplicated protocol designs, extending cycle times by months and increasing patient burden. ?? Sponsors that demonstrate greater precision with outcome measures can select trial sites more easily, recruit patients more quickly, and collect higher-quality data from those patients – all of which leads to a better return on investment. ?? Read more in FirstWord HealthTech, here: https://lnkd.in/esb6jbKN #ClinicalTrials #AI #DigitalTwins #Data

Lengthy trial timelines and increasing trial costs continue to plague the biopharmaceutical industry. Our new global analysis leveraging data from our AI-driven Trial Accelerator? platform examines the impact of trial complexity by modelling the number of outcome measures in a protocol. It shows that the overcollection of data adds months to clinical trials, increases patient burden, and reduces return on investment. Phesi is calling for sponsors to look more closely at their protocols to ensure they do not include an unnecessarily large number of outcome measures. Get in touch to find out how we can help you optimize protocol design and get treatments to patients faster. Download our report here: https://lnkd.in/eeDQ6jzW #clinicaltrials #patientenrollment #AI

??Our Founder and President Gen Li, PhD, MBA shared his insights with Targeted Oncology on how #digitaltwins are changing the game for clinical trials. In the interview, Gen explains the benefits of developing digital twins for clinical trials, delving into the findings from Phesi’s recent GvHD study. ?? ?? Watch the full video here: https://lnkd.in/eQQGcZfF

?? In case you missed it, our Founder and President Gen Li, PhD, MBA spoke to The Medicine Maker about how #DigitalTwinTechnology is transforming clinical trials. Check out the full article below. ?? #ClinicalTrials #AI #DigitalTwins #Data #PatientCare

For those focused on patient recruitment, the Phesi Investigator Site Profile offers a valuable tool for enhancing investigator site enrollment performance. This tool provides quantifiable performance scores based on enrollment, site activation, and patient data quality, offering incremental improvements to your existing toolkit. Developed and validated by clients over 18 years, it has supported the development of prominent medications like Keytruda and Kisunla. If boosting site performance is your goal, this could be a game-changer for you. #clinicaltrials #clinicaldevelopment #patientrecruitment #patientenrollment #clinicaloperations

?? Check out Scientist Live's take on our new self-service Investigator Site Profile solution. Investigator Site Profile is designed to eliminate non-active and non-enrolling investigator sites from #ClinicalDevelopment programmes, helping to reduce unnecessary costs and accelerate cycle times. ?? Users can leverage data from our AI-powered Trial Accelerator? platform to select locations with precision and confidence, streamlining the trial site selection process and optimising outcomes. ?????? ?? Read more, here: https://lnkd.in/eqrvP8uU #AI #ClinicalTrials

?? In case you missed it, check out the latest article from our Founder and President Gen Li, PhD, MBA on how digital twins offer huge potential to not only reduce patient burden but accelerate #ClinicalDevelopment and lower costs. ?? Read the full article in Applied Clinical Trials Magazine September issue on pp. 20-21, here: https://lnkd.in/epiRH9eU #AI #ClinicalTrials #Data #DigitalTwins